ANTAGONIST OF TRPV1 RECEPTOR

Transient Receptor Potential Vanillaoid-1 (TRPV1) mediates pain and inflammation. Stimuli, such as heat, protons, and chemical ligands, generate action potentials that release neurotransmitters and neuroactive peptides to stimulate nerves causing a painful, burning sensation. Studies indicate inhibiting TRPV1 could suppress pain, as well as treat chronic pain and inflammatory hyperalgesia.

The proposed invention is a series of peptides that act as TRPV1 channel antagonists. These peptides are delivered to the TRPV1 channel using a carrier that prevents off-site toxicity, but still allows the antagonist to bind to the TRPV1 channel. The peptides can be delivered topically or intravenously for use in pain treatment.